Taxus Cardium Pharmaceuticals Group Inc (CRXM)

[Altitrade Partners]

Talking about ongoing dilution, without having any facts to substantiate such a claim, serves no purpose other than to fan the flames of unbridled speculation.

With a capital infusion of $1.7 million by Nostrum, less than a year ago, it seems unlikely that they would need to dilute existing shareholder equity by selling large quantities of stock.

It all hinges on what their burn rate has been during the past 10 months, but we can’t imagine that Nostrum hasn’t had a say in how money is being spent.

We will get the answers to this, and other questions, once they file the Super 10-K.

In the meantime, patience and perspective are necessary for CRXM investors.